For the treatment of pancreatic cancer, "sci-fi-level" therapy is approved for clinical trials
For the treatment of pancreatic cancer, "sci-fi-level" therapy is approved for clinical trials
December 21, 2017 Source: WuXi PharmaTech
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];Novocure recently announced that it has received approval from the FDA Medical Device Clinical Trial Exemption (IDE) to launch a clinical trial called PANOVA 3. This randomized phase 3 critical clinical trial was designed to test the efficacy and safety of its new pancreatic cancer combination therapy. The new combination therapy combines Novocure's TTFields with protein-binding paclitaxel and gemcitabine to treat unresectable locally advanced pancreatic cancer.
In 2017, pancreatic cancer became the third-highest cancer in the United States. The 5-year survival rate for patients with pancreatic cancer is only 8%. It is estimated that about 53,000 people were diagnosed with pancreatic cancer in 2017 alone, and about 43,000 people died of the disease. Worldwide, more than 330,000 people die of pancreatic cancer each year. Therefore, the development of treatment options for pancreatic cancer is particularly important.
Novocure has developed a new proprietary TTFields treatment for the treatment of various solid tumors. It is a low-intensity alternating electric field that acts to treat tumor cells by destroying key molecules during cell division during physical mitosis.
PANOVA 3 is a randomized open-label trial of 556 patients with unresectable locally advanced pancreatic cancer. The patient's ECOG performance level must be in the range of 0-2 and no prior treatment has been received. Patients in the experimental group will be treated with a TTFields delivery system at a frequency of 150 kHZ for at least 18 hours, or until treatment is relieved. The primary endpoint of the trial was overall survival. Secondary endpoints included progression-free survival, local progression-free survival, objective response, one-year survival, quality of life, painless survival, resectability, and toxicity.
Novocure accelerated the experimental design of PANOVA 3 after a phase 2 clinical trial of TTFields with nab-paclitaxel and gemcitabine in patients with advanced pancreatic cancer. Compared with the control group (only treated with white-binding paclitaxel and gemcitabine), the progression-free survival and one-year survival rate of this combination therapy more than doubled.
â–² Dr. Daniel D. Von Hoff believes that we need new treatments for pancreatic cancer (Source: Translational Genomics Research Institute)
“Although there is extensive clinical research on pancreatic cancer at this stage, it remains the third-highest cancer in the United States in 2017,†said Daniel D. Von, Distinguished Professor and Research Fellow at the Translational Genomics Research Institute. Dr. Hoff said: "Almost all patients with pancreatic cancer are diagnosed when the tumor has deteriorated and cannot be removed. Until the survival of patients with pancreatic cancer improves, we must always develop and evaluate potential new therapies."
â–² Dr. Eilon Kirson, Chief Scientific Officer of Novocure (Source: Novocure)
Dr. Eilon Kirson, Chief Scientific Officer and Head of Research and Development at Novocure, said: "PANOVA 3 is a key phase 3 trial outside Novocure's third glioblastoma, demonstrating our commitment to developing TTFields for the treatment of various solid tumors. Determined. After obtaining the approval of the FDA's IDE, we will work closely with the testing sites and institutional review committees to open the website and recruit patients for trials as soon as possible."
We hope that this new pancreatic cancer combination therapy will be available soon, benefiting more patients with pancreatic cancer.
Reference materials:
[1] Novocure Receives FDA IDE Approval for Its PANOVA 3 Phase III Pivotal Clinical Trial in Advanced Pancreatic Cancer
[2] Novocure official website
Food Additives,Natural Food Additives,Food Additive Saccharin,Popular Food Additives
SHANDONG BAISHENG BIOTECHNOLOGY CO., LTD , https://www.baishengbioproducts.com